JP2020505448A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505448A5 JP2020505448A5 JP2019559015A JP2019559015A JP2020505448A5 JP 2020505448 A5 JP2020505448 A5 JP 2020505448A5 JP 2019559015 A JP2019559015 A JP 2019559015A JP 2019559015 A JP2019559015 A JP 2019559015A JP 2020505448 A5 JP2020505448 A5 JP 2020505448A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- composition according
- effective amount
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 51
- 150000001875 compounds Chemical class 0.000 claims description 26
- 239000000651 prodrug Substances 0.000 claims description 18
- 229940002612 prodrug Drugs 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 208000023105 Huntington disease Diseases 0.000 claims description 16
- 102000011690 Adiponectin Human genes 0.000 claims description 13
- 108010076365 Adiponectin Proteins 0.000 claims description 13
- 210000000577 adipose tissue Anatomy 0.000 claims description 8
- 230000004153 glucose metabolism Effects 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 8
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 210000001789 adipocyte Anatomy 0.000 claims description 4
- 230000036528 appetite Effects 0.000 claims description 4
- 235000019789 appetite Nutrition 0.000 claims description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 4
- 210000004958 brain cell Anatomy 0.000 claims description 4
- 230000001934 delay Effects 0.000 claims description 4
- 230000010120 metabolic dysregulation Effects 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 230000003442 weekly effect Effects 0.000 claims description 4
- 230000004580 weight loss Effects 0.000 claims description 4
- 230000003203 everyday effect Effects 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447741P | 2017-01-18 | 2017-01-18 | |
| US62/447,741 | 2017-01-18 | ||
| PCT/US2018/014240 WO2018136635A1 (en) | 2017-01-18 | 2018-01-18 | Pparϒ agonist for the treatment of huntington's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505448A JP2020505448A (ja) | 2020-02-20 |
| JP2020505448A5 true JP2020505448A5 (enExample) | 2021-02-25 |
Family
ID=62908392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559015A Pending JP2020505448A (ja) | 2017-01-18 | 2018-01-18 | ハンチントン病の治療のためのＰＰＡＲγアゴニスト |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190350918A1 (enExample) |
| EP (1) | EP3570841A4 (enExample) |
| JP (1) | JP2020505448A (enExample) |
| KR (1) | KR20190122664A (enExample) |
| CN (1) | CN110461330A (enExample) |
| AU (1) | AU2018210165A1 (enExample) |
| BR (1) | BR112019014529A2 (enExample) |
| CA (1) | CA3050104A1 (enExample) |
| EA (1) | EA201991716A1 (enExample) |
| IL (1) | IL268008A (enExample) |
| MX (1) | MX2019008535A (enExample) |
| SG (1) | SG11201906644YA (enExample) |
| WO (1) | WO2018136635A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016144862A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| KR20200036808A (ko) | 2017-04-03 | 2020-04-07 | 코히러스 바이오사이언시스, 인크. | 진행성 핵상 마비 치료를 위한 PPARγ 작용제 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8895541B2 (en) * | 2002-09-04 | 2014-11-25 | James A. Carnazza | Methods for inhibiting the development of huntington's disease |
| US20040224995A1 (en) * | 2003-05-09 | 2004-11-11 | University Of North Texas Health Science Center At Fort Worth | Neuroprotective effects of PPARy agonists against cellular oxidative insults |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| DE10351744A1 (de) * | 2003-10-31 | 2005-06-16 | Schering Ag | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| AU2005295878A1 (en) * | 2004-10-13 | 2006-04-27 | University Of Connecticut | Cannabinergic lipid ligands |
| WO2009097996A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms |
| US20100087481A1 (en) * | 2008-10-03 | 2010-04-08 | Lee Kathleen M | Oral pharmaceutical formulations for antidiabetic compounds |
| US9028879B2 (en) * | 2009-07-01 | 2015-05-12 | Jds Therapeutics, Llc | Chromium complexes as enhancers of brain glucose transporters |
| WO2015095548A1 (en) * | 2013-12-20 | 2015-06-25 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to delay huntington's disease progression |
-
2018
- 2018-01-18 CN CN201880007571.4A patent/CN110461330A/zh active Pending
- 2018-01-18 SG SG11201906644YA patent/SG11201906644YA/en unknown
- 2018-01-18 US US16/476,979 patent/US20190350918A1/en not_active Abandoned
- 2018-01-18 JP JP2019559015A patent/JP2020505448A/ja active Pending
- 2018-01-18 AU AU2018210165A patent/AU2018210165A1/en not_active Abandoned
- 2018-01-18 EA EA201991716A patent/EA201991716A1/ru unknown
- 2018-01-18 EP EP18741523.7A patent/EP3570841A4/en not_active Withdrawn
- 2018-01-18 KR KR1020197023202A patent/KR20190122664A/ko not_active Ceased
- 2018-01-18 CA CA3050104A patent/CA3050104A1/en not_active Abandoned
- 2018-01-18 MX MX2019008535A patent/MX2019008535A/es unknown
- 2018-01-18 BR BR112019014529-0A patent/BR112019014529A2/pt not_active Application Discontinuation
- 2018-01-18 WO PCT/US2018/014240 patent/WO2018136635A1/en not_active Ceased
-
2019
- 2019-07-11 IL IL268008A patent/IL268008A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2577930T3 (es) | Derivados de triazina para retrasar el inicio de la diabetes tipo 1 | |
| JP2020536905A5 (enExample) | ||
| JP7265990B2 (ja) | 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 | |
| JP2013545730A5 (enExample) | ||
| MX2015017307A (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. | |
| JP2016193932A5 (enExample) | ||
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EP3226873B1 (en) | Compositions comprising 15-hepe and its use for treating or preventing idiopathic pulomonary fibrosis | |
| RU2010143864A (ru) | Способы лечения нарушений с применением селективного антагониста nr2b-подтипа nmda рецепторов | |
| BG108379A (bg) | Използване на енантиомерно чист есциталопрам | |
| JP2018538306A5 (enExample) | ||
| JP2020505448A5 (enExample) | ||
| IL292770A (en) | Formulations and doses of pegylated uricase | |
| RU2005131845A (ru) | Способ лечения легкого ухудшения познавательной способности и предотвращения или задержки начала болезни альцгеймера | |
| RU2012150501A (ru) | Противораковые стероидные лактоны, ненасыщенные в положении 7(8) | |
| BR112012022052A2 (pt) | método para o tratamento ou prevenção de sintomas da variação hormonal, composição farmacêutica para o tratamento ou prevenção de sintomas da variação hormonal e kit para o tratamento ou prevenção de sintomas da variação hormonal | |
| JP2019507786A5 (enExample) | ||
| JP2019524888A5 (enExample) | ||
| JP2019524888A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| JP2019531286A5 (enExample) | ||
| JP2020531543A5 (enExample) | ||
| JP2020533402A5 (enExample) | ||
| JP2019515033A5 (enExample) | ||
| RU2013157834A (ru) | Композиции для подкожного введения физиологически активных средств |